01388nas a2200481   4500000000100000000000100001000000100002008004100003653001000044653001100054653001100065653001600076653000900092653007100101653003100172653001900203653004000222653001200262653004800274653002400322653003200346653001300378653003000391653003000421653001400451100001300465700001900478700001500497700001500512700001700527700001400544700001400558700001600572700001800588700001600606700001600622700001400638700001900652245019900671250001500870490000700885020001400892       2024                            d10aAdult10aHumans10aFemale10aMiddle Aged10aMale10a*Diabetes Mellitus, Type 2/complications/drug therapy/epidemiology10a*Metformin/adverse effects10aCohort Studies10aHypoglycemic Agents/adverse effects10aGlucose10a*Dementia/epidemiology/prevention & control10aPrimary health care10aUnited Kingdom/epidemiology10adementia10adiabetes mellitus, type 210aElectronic Health Records10ametformin1 aW. Doran1 aL. Tunnicliffe1 aR. Muzambi1 aC. Rentsch1 aK. Bhaskaran1 aL. Smeeth1 aC. Brayne1 aD. Williams1 aN. Chaturvedi1 aS. Eastwood1 aS. Dunachie1 aR. Mathur1 aC. Warren-Gash00aIncident dementia risk among patients with type 2 diabetes receiving metformin versus alternative oral glucose-lowering therapy: an observational cohort study using UK primary healthcare records  a2024/01/260 v12  a2052-4897